Copyright Reports & Markets. All rights reserved.

Global Toxic Epidermal Necrolysis (TEN) Market 2026 by Company, Regions, Type and Application, Forecast to 2032

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Classification of Toxic Epidermal Necrolysis (TEN) by Type
    • 1.3.1 Overview: Global Toxic Epidermal Necrolysis (TEN) Market Size by Type: 2021 Versus 2025 Versus 2032
    • 1.3.2 Global Toxic Epidermal Necrolysis (TEN) Consumption Value Market Share by Type in 2025
    • 1.3.3 Neonatal Patients
    • 1.3.4 Adolescent Patients
    • 1.3.5 Adult Patients
  • 1.4 Global Toxic Epidermal Necrolysis (TEN) Market by Application
    • 1.4.1 Overview: Global Toxic Epidermal Necrolysis (TEN) Market Size by Application: 2021 Versus 2025 Versus 2032
    • 1.4.2 Hospital
    • 1.4.3 Diagnostic Center
    • 1.4.4 Others
  • 1.5 Global Toxic Epidermal Necrolysis (TEN) Market Size & Forecast
  • 1.6 Global Toxic Epidermal Necrolysis (TEN) Market Size and Forecast by Region
    • 1.6.1 Global Toxic Epidermal Necrolysis (TEN) Market Size by Region: 2021 VS 2025 VS 2032
    • 1.6.2 Global Toxic Epidermal Necrolysis (TEN) Market Size by Region, (2021-2032)
    • 1.6.3 North America Toxic Epidermal Necrolysis (TEN) Market Size and Prospect (2021-2032)
    • 1.6.4 Europe Toxic Epidermal Necrolysis (TEN) Market Size and Prospect (2021-2032)
    • 1.6.5 Asia-Pacific Toxic Epidermal Necrolysis (TEN) Market Size and Prospect (2021-2032)
    • 1.6.6 South America Toxic Epidermal Necrolysis (TEN) Market Size and Prospect (2021-2032)
    • 1.6.7 Middle East & Africa Toxic Epidermal Necrolysis (TEN) Market Size and Prospect (2021-2032)

2 Company Profiles

  • 2.1 Mölnlycke Health Care
    • 2.1.1 Mölnlycke Health Care Details
    • 2.1.2 Mölnlycke Health Care Major Business
    • 2.1.3 Mölnlycke Health Care Toxic Epidermal Necrolysis (TEN) Product and Solutions
    • 2.1.4 Mölnlycke Health Care Toxic Epidermal Necrolysis (TEN) Revenue, Gross Margin and Market Share (2021-2026)
    • 2.1.5 Mölnlycke Health Care Recent Developments and Future Plans
  • 2.2 maxill inc
    • 2.2.1 maxill inc Details
    • 2.2.2 maxill inc Major Business
    • 2.2.3 maxill inc Toxic Epidermal Necrolysis (TEN) Product and Solutions
    • 2.2.4 maxill inc Toxic Epidermal Necrolysis (TEN) Revenue, Gross Margin and Market Share (2021-2026)
    • 2.2.5 maxill inc Recent Developments and Future Plans
  • 2.3 Cadila Pharmaceuticals
    • 2.3.1 Cadila Pharmaceuticals Details
    • 2.3.2 Cadila Pharmaceuticals Major Business
    • 2.3.3 Cadila Pharmaceuticals Toxic Epidermal Necrolysis (TEN) Product and Solutions
    • 2.3.4 Cadila Pharmaceuticals Toxic Epidermal Necrolysis (TEN) Revenue, Gross Margin and Market Share (2021-2026)
    • 2.3.5 Cadila Pharmaceuticals Recent Developments and Future Plans
  • 2.4 BD
    • 2.4.1 BD Details
    • 2.4.2 BD Major Business
    • 2.4.3 BD Toxic Epidermal Necrolysis (TEN) Product and Solutions
    • 2.4.4 BD Toxic Epidermal Necrolysis (TEN) Revenue, Gross Margin and Market Share (2021-2026)
    • 2.4.5 BD Recent Developments and Future Plans
  • 2.5 Schulke India Pvt. Ltd
    • 2.5.1 Schulke India Pvt. Ltd Details
    • 2.5.2 Schulke India Pvt. Ltd Major Business
    • 2.5.3 Schulke India Pvt. Ltd Toxic Epidermal Necrolysis (TEN) Product and Solutions
    • 2.5.4 Schulke India Pvt. Ltd Toxic Epidermal Necrolysis (TEN) Revenue, Gross Margin and Market Share (2021-2026)
    • 2.5.5 Schulke India Pvt. Ltd Recent Developments and Future Plans
  • 2.6 Smith & Nephew
    • 2.6.1 Smith & Nephew Details
    • 2.6.2 Smith & Nephew Major Business
    • 2.6.3 Smith & Nephew Toxic Epidermal Necrolysis (TEN) Product and Solutions
    • 2.6.4 Smith & Nephew Toxic Epidermal Necrolysis (TEN) Revenue, Gross Margin and Market Share (2021-2026)
    • 2.6.5 Smith & Nephew Recent Developments and Future Plans
  • 2.7 Basic Pharma Life Science P Ltd.
    • 2.7.1 Basic Pharma Life Science P Ltd. Details
    • 2.7.2 Basic Pharma Life Science P Ltd. Major Business
    • 2.7.3 Basic Pharma Life Science P Ltd. Toxic Epidermal Necrolysis (TEN) Product and Solutions
    • 2.7.4 Basic Pharma Life Science P Ltd. Toxic Epidermal Necrolysis (TEN) Revenue, Gross Margin and Market Share (2021-2026)
    • 2.7.5 Basic Pharma Life Science P Ltd. Recent Developments and Future Plans
  • 2.8 PSK Pharma
    • 2.8.1 PSK Pharma Details
    • 2.8.2 PSK Pharma Major Business
    • 2.8.3 PSK Pharma Toxic Epidermal Necrolysis (TEN) Product and Solutions
    • 2.8.4 PSK Pharma Toxic Epidermal Necrolysis (TEN) Revenue, Gross Margin and Market Share (2021-2026)
    • 2.8.5 PSK Pharma Recent Developments and Future Plans
  • 2.9 Avrio Health L.P.
    • 2.9.1 Avrio Health L.P. Details
    • 2.9.2 Avrio Health L.P. Major Business
    • 2.9.3 Avrio Health L.P. Toxic Epidermal Necrolysis (TEN) Product and Solutions
    • 2.9.4 Avrio Health L.P. Toxic Epidermal Necrolysis (TEN) Revenue, Gross Margin and Market Share (2021-2026)
    • 2.9.5 Avrio Health L.P. Recent Developments and Future Plans
  • 2.10 3M
    • 2.10.1 3M Details
    • 2.10.2 3M Major Business
    • 2.10.3 3M Toxic Epidermal Necrolysis (TEN) Product and Solutions
    • 2.10.4 3M Toxic Epidermal Necrolysis (TEN) Revenue, Gross Margin and Market Share (2021-2026)
    • 2.10.5 3M Recent Developments and Future Plans
  • 2.11 Biesterfeld AG
    • 2.11.1 Biesterfeld AG Details
    • 2.11.2 Biesterfeld AG Major Business
    • 2.11.3 Biesterfeld AG Toxic Epidermal Necrolysis (TEN) Product and Solutions
    • 2.11.4 Biesterfeld AG Toxic Epidermal Necrolysis (TEN) Revenue, Gross Margin and Market Share (2021-2026)
    • 2.11.5 Biesterfeld AG Recent Developments and Future Plans
  • 2.12 Vesismin Health
    • 2.12.1 Vesismin Health Details
    • 2.12.2 Vesismin Health Major Business
    • 2.12.3 Vesismin Health Toxic Epidermal Necrolysis (TEN) Product and Solutions
    • 2.12.4 Vesismin Health Toxic Epidermal Necrolysis (TEN) Revenue, Gross Margin and Market Share (2021-2026)
    • 2.12.5 Vesismin Health Recent Developments and Future Plans
  • 2.13 Mylan N.V.
    • 2.13.1 Mylan N.V. Details
    • 2.13.2 Mylan N.V. Major Business
    • 2.13.3 Mylan N.V. Toxic Epidermal Necrolysis (TEN) Product and Solutions
    • 2.13.4 Mylan N.V. Toxic Epidermal Necrolysis (TEN) Revenue, Gross Margin and Market Share (2021-2026)
    • 2.13.5 Mylan N.V. Recent Developments and Future Plans

3 Market Competition, by Players

  • 3.1 Global Toxic Epidermal Necrolysis (TEN) Revenue and Share by Players (2021-2026)
  • 3.2 Market Share Analysis (2025)
    • 3.2.1 Market Share of Toxic Epidermal Necrolysis (TEN) by Company Revenue
    • 3.2.2 Top 3 Toxic Epidermal Necrolysis (TEN) Players Market Share in 2025
    • 3.2.3 Top 6 Toxic Epidermal Necrolysis (TEN) Players Market Share in 2025
  • 3.3 Toxic Epidermal Necrolysis (TEN) Market: Overall Company Footprint Analysis
    • 3.3.1 Toxic Epidermal Necrolysis (TEN) Market: Region Footprint
    • 3.3.2 Toxic Epidermal Necrolysis (TEN) Market: Company Product Type Footprint
    • 3.3.3 Toxic Epidermal Necrolysis (TEN) Market: Company Product Application Footprint
  • 3.4 New Market Entrants and Barriers to Market Entry
  • 3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type

  • 4.1 Global Toxic Epidermal Necrolysis (TEN) Consumption Value and Market Share by Type (2021-2026)
  • 4.2 Global Toxic Epidermal Necrolysis (TEN) Market Forecast by Type (2027-2032)

5 Market Size Segment by Application

  • 5.1 Global Toxic Epidermal Necrolysis (TEN) Consumption Value Market Share by Application (2021-2026)
  • 5.2 Global Toxic Epidermal Necrolysis (TEN) Market Forecast by Application (2027-2032)

6 North America

  • 6.1 North America Toxic Epidermal Necrolysis (TEN) Consumption Value by Type (2021-2032)
  • 6.2 North America Toxic Epidermal Necrolysis (TEN) Market Size by Application (2021-2032)
  • 6.3 North America Toxic Epidermal Necrolysis (TEN) Market Size by Country
    • 6.3.1 North America Toxic Epidermal Necrolysis (TEN) Consumption Value by Country (2021-2032)
    • 6.3.2 United States Toxic Epidermal Necrolysis (TEN) Market Size and Forecast (2021-2032)
    • 6.3.3 Canada Toxic Epidermal Necrolysis (TEN) Market Size and Forecast (2021-2032)
    • 6.3.4 Mexico Toxic Epidermal Necrolysis (TEN) Market Size and Forecast (2021-2032)

7 Europe

  • 7.1 Europe Toxic Epidermal Necrolysis (TEN) Consumption Value by Type (2021-2032)
  • 7.2 Europe Toxic Epidermal Necrolysis (TEN) Consumption Value by Application (2021-2032)
  • 7.3 Europe Toxic Epidermal Necrolysis (TEN) Market Size by Country
    • 7.3.1 Europe Toxic Epidermal Necrolysis (TEN) Consumption Value by Country (2021-2032)
    • 7.3.2 Germany Toxic Epidermal Necrolysis (TEN) Market Size and Forecast (2021-2032)
    • 7.3.3 France Toxic Epidermal Necrolysis (TEN) Market Size and Forecast (2021-2032)
    • 7.3.4 United Kingdom Toxic Epidermal Necrolysis (TEN) Market Size and Forecast (2021-2032)
    • 7.3.5 Russia Toxic Epidermal Necrolysis (TEN) Market Size and Forecast (2021-2032)
    • 7.3.6 Italy Toxic Epidermal Necrolysis (TEN) Market Size and Forecast (2021-2032)

8 Asia-Pacific

  • 8.1 Asia-Pacific Toxic Epidermal Necrolysis (TEN) Consumption Value by Type (2021-2032)
  • 8.2 Asia-Pacific Toxic Epidermal Necrolysis (TEN) Consumption Value by Application (2021-2032)
  • 8.3 Asia-Pacific Toxic Epidermal Necrolysis (TEN) Market Size by Region
    • 8.3.1 Asia-Pacific Toxic Epidermal Necrolysis (TEN) Consumption Value by Region (2021-2032)
    • 8.3.2 China Toxic Epidermal Necrolysis (TEN) Market Size and Forecast (2021-2032)
    • 8.3.3 Japan Toxic Epidermal Necrolysis (TEN) Market Size and Forecast (2021-2032)
    • 8.3.4 South Korea Toxic Epidermal Necrolysis (TEN) Market Size and Forecast (2021-2032)
    • 8.3.5 India Toxic Epidermal Necrolysis (TEN) Market Size and Forecast (2021-2032)
    • 8.3.6 Southeast Asia Toxic Epidermal Necrolysis (TEN) Market Size and Forecast (2021-2032)
    • 8.3.7 Australia Toxic Epidermal Necrolysis (TEN) Market Size and Forecast (2021-2032)

9 South America

  • 9.1 South America Toxic Epidermal Necrolysis (TEN) Consumption Value by Type (2021-2032)
  • 9.2 South America Toxic Epidermal Necrolysis (TEN) Consumption Value by Application (2021-2032)
  • 9.3 South America Toxic Epidermal Necrolysis (TEN) Market Size by Country
    • 9.3.1 South America Toxic Epidermal Necrolysis (TEN) Consumption Value by Country (2021-2032)
    • 9.3.2 Brazil Toxic Epidermal Necrolysis (TEN) Market Size and Forecast (2021-2032)
    • 9.3.3 Argentina Toxic Epidermal Necrolysis (TEN) Market Size and Forecast (2021-2032)

10 Middle East & Africa

  • 10.1 Middle East & Africa Toxic Epidermal Necrolysis (TEN) Consumption Value by Type (2021-2032)
  • 10.2 Middle East & Africa Toxic Epidermal Necrolysis (TEN) Consumption Value by Application (2021-2032)
  • 10.3 Middle East & Africa Toxic Epidermal Necrolysis (TEN) Market Size by Country
    • 10.3.1 Middle East & Africa Toxic Epidermal Necrolysis (TEN) Consumption Value by Country (2021-2032)
    • 10.3.2 Turkey Toxic Epidermal Necrolysis (TEN) Market Size and Forecast (2021-2032)
    • 10.3.3 Saudi Arabia Toxic Epidermal Necrolysis (TEN) Market Size and Forecast (2021-2032)
    • 10.3.4 UAE Toxic Epidermal Necrolysis (TEN) Market Size and Forecast (2021-2032)

11 Market Dynamics

  • 11.1 Toxic Epidermal Necrolysis (TEN) Market Drivers
  • 11.2 Toxic Epidermal Necrolysis (TEN) Market Restraints
  • 11.3 Toxic Epidermal Necrolysis (TEN) Trends Analysis
  • 11.4 Porters Five Forces Analysis
    • 11.4.1 Threat of New Entrants
    • 11.4.2 Bargaining Power of Suppliers
    • 11.4.3 Bargaining Power of Buyers
    • 11.4.4 Threat of Substitutes
    • 11.4.5 Competitive Rivalry

12 Industry Chain Analysis

  • 12.1 Toxic Epidermal Necrolysis (TEN) Industry Chain
  • 12.2 Toxic Epidermal Necrolysis (TEN) Upstream Analysis
  • 12.3 Toxic Epidermal Necrolysis (TEN) Midstream Analysis
  • 12.4 Toxic Epidermal Necrolysis (TEN) Downstream Analysis

13 Research Findings and Conclusion

    14 Appendix

    • 14.1 Methodology
    • 14.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global Toxic Epidermal Necrolysis (TEN) market size was valued at US$ 985 million in 2025 and is forecast to a readjusted size of US$ 1292 million by 2032 with a CAGR of 4.0% during review period.
    Toxic epidermal necrolysis (TEN) is a rare and serious skin condition. Often, it’s caused by an adverse reaction to medication like anticonvulsants or antibiotics.The main symptom is severe skin peeling and blistering. The peeling progresses quickly, resulting in large raw areas that may ooze or weep. It also affects the mucous membranes, including the mouth, throat, eyes, and genital region.
    The global toxic epidermal necrolysis (TEN) market refers to the market for diagnostic tests, treatments, therapies, and related products and services for the management of TEN. TEN is a rare, life-threatening condition characterized by widespread skin necrosis and detachment, often triggered by a severe drug reaction. Here are some key points regarding the global TEN market:
    Market Growth: The market for TEN management has witnessed growth due to various factors. Increased awareness among healthcare professionals, improved diagnostic techniques, and advancements in treatment options contribute to market expansion.
    Prevalence: TEN is a relatively rare condition, with an estimated prevalence ranging from 0.4 to 1.2 cases per million population per year. However, it is associated with significant morbidity and mortality rates. The exact prevalence may vary across regions and populations.
    Diagnosis: Early and accurate diagnosis of TEN is crucial for prompt intervention. Diagnosis typically involves clinical evaluation, skin biopsies, and sometimes laboratory tests. Efforts are underway to develop more specific and rapid diagnostic tools for early detection.
    Treatment: The primary goal of treatment for TEN is to prevent further skin detachment, manage complications, and provide supportive care. Treatment measures may include discontinuation of triggering drugs, wound care, fluid and electrolyte management, pain control, nutritional support, and prevention of infection. Immunosuppressant medications and immunoglobulins may be utilized in certain cases.
    Research and Development: Ongoing research aims to enhance the understanding of the underlying mechanisms of TEN and develop more effective treatment approaches. Clinical trials and studies focus on evaluating new therapeutic agents, wound management strategies, and molecular targets for intervention.
    Key Players: The market for TEN management includes pharmaceutical companies, biotechnology firms, and healthcare institutions.
    Challenges: The management of TEN poses several challenges, including the need for rapid and accurate diagnosis, limited treatment options, high healthcare costs, and potential long-term complications for survivors. Additionally, the rarity of the condition makes conducting clinical trials and gathering sufficient data challenging.
    Efforts are being made to improve the overall management and outcomes of TEN. Collaborative research, awareness campaigns, and investment in innovative therapies are expected to drive the growth of the global TEN market in the coming years. The ultimate goal is to reduce morbidity and mortality rates associated with this severe condition.
    This report is a detailed and comprehensive analysis for global Toxic Epidermal Necrolysis (TEN) market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
    Key Features:
    Global Toxic Epidermal Necrolysis (TEN) market size and forecasts, in consumption value ($ Million), 2021-2032
    Global Toxic Epidermal Necrolysis (TEN) market size and forecasts by region and country, in consumption value ($ Million), 2021-2032
    Global Toxic Epidermal Necrolysis (TEN) market size and forecasts, by Type and by Application, in consumption value ($ Million), 2021-2032
    Global Toxic Epidermal Necrolysis (TEN) market shares of main players, in revenue ($ Million), 2021-2026
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for Toxic Epidermal Necrolysis (TEN)
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global Toxic Epidermal Necrolysis (TEN) market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Mölnlycke Health Care, maxill inc, Cadila Pharmaceuticals, BD, Schulke India Pvt. Ltd, Smith & Nephew, Basic Pharma Life Science P Ltd., PSK Pharma, Avrio Health L.P., 3M, etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
    Market segmentation
    Toxic Epidermal Necrolysis (TEN) market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
    Market segment by Type
    Neonatal Patients
    Adolescent Patients
    Adult Patients
    Market segment by Application
    Hospital
    Diagnostic Center
    Others
    Market segment by players, this report covers
    Mölnlycke Health Care
    maxill inc
    Cadila Pharmaceuticals
    BD
    Schulke India Pvt. Ltd
    Smith & Nephew
    Basic Pharma Life Science P Ltd.
    PSK Pharma
    Avrio Health L.P.
    3M
    Biesterfeld AG
    Vesismin Health
    Mylan N.V.
    Market segment by regions, regional analysis covers
    North America (United States, Canada and Mexico)
    Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
    Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
    South America (Brazil, Rest of South America)
    Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 13 chapters:
    Chapter 1, to describe Toxic Epidermal Necrolysis (TEN) product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top players of Toxic Epidermal Necrolysis (TEN), with revenue, gross margin, and global market share of Toxic Epidermal Necrolysis (TEN) from 2021 to 2026.
    Chapter 3, the Toxic Epidermal Necrolysis (TEN) competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
    Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2021 to 2032.
    Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2021 to 2026.and Toxic Epidermal Necrolysis (TEN) market forecast, by regions, by Type and by Application, with consumption value, from 2027 to 2032.
    Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
    Chapter 12, the key raw materials and key suppliers, and industry chain of Toxic Epidermal Necrolysis (TEN).
    Chapter 13, to describe Toxic Epidermal Necrolysis (TEN) research findings and conclusion.

    Buy now